

FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

-Collaboration results in platform to help researchers overcome challenges in MSC research

-NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences

SANTA ANA, Calif., USA and HUDDINGE, SWEDEN, MAY 06, 2026 – FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences' PRIME-XV MSC Expansion XSFM medium and NextCell's first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue.

Some of the challenges faced in MSC research are heterogeneity of MSCs, immunocompatibility, and inefficient manufacturing. NextCell-Cord RUO provides researchers a more consistent, efficient, and accessible source of cells. The collaboration with FUJIFILM Biosciences to provide these cells with media delivers a high-quality, standardized solution for researchers working in immunology, regenerative medicine, and cell therapy development.

NextCell-Cord RUO is available across all major global markets through FUJIFILM Biosciences as a standalone product or bundled with Fujifilm's PRIME-XV MSC Expansion XSFM media, recombinant growth factors and reagents.

"FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide," said Brandon Pence, president and chief operations officer at FUJIFILM Biosciences. "Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all."

"This product launch is a milestone for NextCell Pharma AB," said Mathias Svahn, chief executive officer of NextCell Pharma AB. "It brings our proprietary MSC platform to a global audience, and we are proud to do so in close collaboration with FUJIFILM Biosciences, a trusted leader in life science solutions."

"We've worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability, and translational relevance," said Dr. Lindsay Davies, chief scientific officer at NextCell Pharma AB. "NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardized MSC products that are scientifically robust and immediately usable in research and development workflows."

ENDS

Notes to Editors

FUJIFILM Biosciences

With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences' Mission has been to enable life changing therapies and vaccines for a healthier world. The Company's facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences operates as a subsidiary of FUJIFILM Holdings America Corporation under FUJIFILM Holdings Corporation.

For more information, please visit: fujifilmbiosciences.fujifilm.com

FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, [click here](#).

About NextCell Pharma AB

NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell's subsidiaries include Cellaviva, Scandinavia's largest private stem cell bank, and QVance, the Nordic region's first dedicated provider of quality services for developers of advanced therapies.

Media Contacts

Lori Serles
FUJIFILM Biosciences
Phone: (949) 261-7800 x145
Email: lori.serles@fujifilm.com

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications, please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

Mathias Svahn, CEO
NextCell Pharma AB
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:

NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: <https://www.linkedin.com/company/15255207/>

X: <https://x.com/NextCellPharma>

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.